Acne

Research from Yuzuncu Yil University yields new data on coagulation therapy

Acne Library Library Home This article was published in Biotech Business Week, which you can subscribe to online.

"The implant was inserted between days 1 and 5 of the menstrual cycle. Findings were recorded before and during 6 months following insertion. Statistical analyses were performed using SPSS package programme including paired samples t-test No pregnancy occurred during the study. Ninety days after initiation of therapy, three of the 41 patients (7.3%) had regular periods, 14 (34.1%) were amenorrhoeic and the remaining 24 (58.5%) had some type of abnormal bleeding. Dysmenorrhoea affected significantly less women (1/41, i.e. 2.4%) than before treatment (17/41, i.e. 41.5%), but mastalgia increased significantly as it was reported by five previously unaffected participants (12.2%). Mood changes appeared in seven patients (17.1%) and acne in 11 of them (26.8%). The circulating levels of protein C, total cholesterol and oestradiol dropped significantly. Endometrial thickness decreased significantly," wrote B. Yildizbas and colleagues, Yuzuncu Yil University.

The researchers concluded: "At completion of the study period, removal of the implant was requested by eight of the 41 patients (19.5%) because of irregular bleeding (six women), depressive symptoms requiring treatment (one woman) or weight gain (one woman) Mainly because of irregular bleeding, the discontinuation rate of Implanon at 6 months among the women in this region is high (19.5%)."

Yildizbas and colleagues published the results of their research in The European Journal of Contraception and Reproductive Health Care (Side effects and acceptability of Implanon: a pilot study conducted in eastern Turkey. The European Journal of Contraception and Reproductive Health Care, 2007;12(3):248-52).

For additional information, contact B. Yildizbas, Yuzuncu Yil University, Dept. of Obstetrics and Gynaecology, Van, Turkey.

The publisher of the The European Journal of Contraception and Reproductive Health Care can be contacted at: Parthenon Publishing Group, Richmond House, White Cross, South Road, Lancaster LA1 4XQ, England.

Keywords: Turkey, Van, Coagulation Therapy, Abnormal Bleeding, Clinical Trial Research, Contraception, Depression, Gynecology, Hematology, Menstruation, Mental Health, Obstetrics, Pregnancy, Reproductive Health, Therapy, Treatment, Women's Health.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.